Guidance on Developing Treatments for Stimulant Use Disorders
FDA has not yet approved any medications for stimulant use disorders.
Critical impact 28 min
Updated daily from FDA, EMA, ICH and leading publishers
The pharma industry's research library
Curated regulatory guidance, clinical analyses, and market reports. AI-summarized, editor-reviewed, instantly downloadable.
2whitepapers
8publishers
6regions
Dailyupdates
Research Pulse
Updated continuously 2 Research reports In library
8 Publishers FDA, EMA, industry
2 Featured Editor picks
0 Gated downloads Lead-gen reports
Browse the library
2 results 
FDA's April 30, 2026 ODAC Meeting on Camizestrant Review
Camizestrant is under review for the treatment of ESR1m/HR+/HER2- advanced breast cancer (ABC).
High impact 198 min